Altered cytokine and nitric oxide secretion in vitro by macrophages from diabetic type II-like db/db mice.

Macrophage dysfunction is a likely mechanism underlying common diabetic complications such as increased susceptibility to infection, accelerated atherosclerosis, and disturbed wound healing. There are no available studies on the function of tissue macrophages in diabetes in humans. We have therefore studied peritoneal macrophages from diabetic type 2-like db/db mice. We found that the release of tumor necrosis factor-alpha and interleukin-1beta from lipopolysaccharide plus interferon-gamma-stimulated macrophages and vascular endothelial growth factor from both stimulated and nonstimulated macrophages was significantly reduced in diabetic animals compared with nondiabetic controls. Nitric oxide production from the stimulated db/db macrophages was significantly higher than that in the db/+ cultures, whereas there was no difference in their ability to generate reactive oxygen species. When studied both at light and electron microscopic levels, macrophages in diabetic animals had an altered morphological appearance compared with those of normal controls. We conclude that the function and morphology of the macrophages are disturbed in db/db mice and that this disturbance is related to the mechanisms underlying common inflammatory and degenerative manifestations in diabetes.

[1]  C. Nathan,et al.  Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. , 1988, Journal of immunology.

[2]  L. Mazzanti,et al.  Evidence for iNOS-dependent peroxynitrite production in diabetic platelets , 1999, Diabetologia.

[3]  H. Hill,et al.  Functional and metabolic abnormalities of diabetic monocytes. , 1982, Advances in experimental medicine and biology.

[4]  P. Efron,et al.  Diabetes-impaired healing and reduced wound nitric oxide synthesis: a possible pathophysiologic correlation. , 1997, Surgery.

[5]  J. Bennedsen,et al.  Monocyte functions in diabetes mellitus. , 2009, Acta pathologica, microbiologica, et immunologica Scandinavica. Section C, Immunology.

[6]  M. Kasuga,et al.  Accumulation of Pyrraline-modified Albumin in Phagocytes due to Reduced Degradation by Lysosomal Enzymes* , 1997, The Journal of Biological Chemistry.

[7]  A. Desfaits,et al.  Normalization of Plasma Lipid Peroxides, Monocyte Adhesion, and Tumor Necrosis Factor-α Production in NIDDM Patients After Gliclazide Treatment , 1998, Diabetes Care.

[8]  P. Damsbo,et al.  Circulating monocytes are activated in newly diagnosed type 1 diabetes mellitus patients , 1994, Clinical and experimental immunology.

[9]  D. Greenhalgh,et al.  Differential expression and localization of insulin-like growth factors I and II in cutaneous wounds of diabetic and nondiabetic mice. , 1997, The American journal of pathology.

[10]  H. Drexhage,et al.  Defective maturation and function of antigen-presenting cells in type 1 diabetes , 1995, The Lancet.

[11]  R. Ross,et al.  The role of the macrophage in wound repair. A study with hydrocortisone and antimacrophage serum. , 1975, The American journal of pathology.

[12]  M. Goppelt‐Struebe,et al.  Fluorometric determination of the DNA content of cells cultured in tissue culture plates. , 1992, Journal of immunological methods.

[13]  A. Rabinovitch,et al.  Tumor necrosis factor production is deficient in diabetes-prone BB rats and can be corrected by complete Freund's adjuvant: a possible immunoregulatory role of tumor necrosis factor in the prevention of diabetes. , 1992, Clinical immunology and immunopathology.

[14]  J. Drapier,et al.  Differentiation of murine macrophages to express nonspecific cytotoxicity for tumor cells results in L-arginine-dependent inhibition of mitochondrial iron-sulfur enzymes in the macrophage effector cells. , 1988, Journal of immunology.

[15]  L. Tartaglia,et al.  Evidence That the Diabetes Gene Encodes the Leptin Receptor: Identification of a Mutation in the Leptin Receptor Gene in db/db Mice , 1996, Cell.

[16]  M. Brownlee,et al.  Glycation Products and the Pathogenesis of Diabetic Complications , 1992, Diabetes Care.

[17]  Ptak,et al.  Macrophage function in alloxan diabetic mice: expression of adhesion molecules, generation of monokines and oxygen and NO radicals , 1998, Clinical and experimental immunology.

[18]  D. Greenhalgh,et al.  PDGF and FGF stimulate wound healing in the genetically diabetic mouse. , 1990, The American journal of pathology.

[19]  N. Shinomiya,et al.  Intracellular hydrogen peroxide production by peripheral phagocytes from diabetic patients. Dissociation between polymorphonuclear leucocytes and monocytes , 1992, Clinical and experimental immunology.

[20]  J. Friedman,et al.  Abnormal splicing of the leptin receptor in diabetic mice , 1996, Nature.

[21]  Gary R. Grotendorst,et al.  Stimulation of granulation tissue formation by platelet-derived growth factor in normal and diabetic rats. , 1985, The Journal of clinical investigation.

[22]  K. Tracey,et al.  Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. , 1991, The Journal of clinical investigation.

[23]  R. Arnold,et al.  Inflammatory mediator response as a potential risk marker for periodontal diseases in insulin-dependent diabetes mellitus patients. , 1997, Journal of periodontology.

[24]  C. Secombes Isolation of salmonid macrophages and analysis of their killing activity , 1990 .

[25]  M. Bitar Insulin-Like Growth Factor-1 Reverses Diabetes-Induced Wound Healing Impairment in Rats , 1997, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[26]  B. Kulseng,et al.  TNF Production from Peripheral Blood Mononuclear Cells in Diabetic Patients after Stimulation with Alginate and Lipopolysaccharide , 1996, Scandinavian journal of immunology.

[27]  M. Lane,et al.  Leptin regulates proinflammatory immune responses. , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[28]  Y. Ohno,et al.  In vitro production of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in insulin-dependent diabetes mellitus. , 1993, The Journal of clinical endocrinology and metabolism.

[29]  S. Marshall,et al.  Dysregulation of PMN antigen expression in Type 2 diabetes may reflect a generalized defect of exocytosis: influence of hypertension and microalbuminuria , 1999, Journal of leukocyte biology.

[30]  G. Grunberger,et al.  Receptor-mediated endocytosis of insulin: inhibition of [125I]iodoinsulin internalization in insulin resistant diabetic states of man. , 1989, Acta endocrinologica.

[31]  K Takahashi,et al.  Immunohistochemical distribution and subcellular localization of three distinct specific molecular structures of advanced glycation end products in human tissues. , 1998, Laboratory investigation; a journal of technical methods and pathology.

[32]  T. Luger,et al.  Cytokine production in patients with newly diagnosed insulin‐dependent (type I) diabetes mellitus , 1988, European journal of clinical investigation.

[33]  P. Fishman,et al.  Phagocytotic Activity of Monocytes from Diabetic Patients , 1983, Diabetes Care.

[34]  D. Sutherland,et al.  Insulin down-regulates the inducible nitric oxide synthase pathway: nitric oxide as cause and effect of diabetes? , 1997, Journal of Immunology.

[35]  M. Knip,et al.  Defective HLA class II expression in monocytes of type 1 diabetic patients , 1993, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[36]  F. Chang,et al.  Respiratory burst activity of monocytes from patients with non-insulin-dependent diabetes mellitus. , 1995, Diabetes research and clinical practice.

[37]  M. Ferguson,et al.  The role of nitric oxide synthase isoforms and arginase in the pathogenesis of diabetic foot ulcers: possible modulatory effects by transforming growth factor beta 1 , 1999, Diabetologia.

[38]  M. Caldwell,et al.  Regulation of macrophage functions by L-arginine , 1989, The Journal of experimental medicine.

[39]  C. Cutler,et al.  Diabetes-induced impairment of macrophage cytokine release in a rat model: potential role of serum lipids. , 1998, Life sciences.

[40]  M. Mcdaniel,et al.  Hyperglycemic Levels of Glucose Inhibit Interleukin 1 Release from RAW 264.7 Murine Macrophages by Activation of Protein Kinase C* , 1998, The Journal of Biological Chemistry.

[41]  G. A. Holloway,et al.  Randomized Prospective Double-Blind Trial in Healing Chronic Diabetic Foot Ulcers: CT-102 activated platelet supernatant, topical versus placebo , 1992, Diabetes Care.

[42]  R. Arnold,et al.  Monocytic TNF alpha secretion patterns in IDDM patients with periodontal diseases. , 1997, Journal of clinical periodontology.